Autopsy report · NCT03626701
RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years
Cause of deathRegulatory or ethics
“In June 2021, the US FDA approved expanded use of the RECELL System for treatment of acute full-thickness thermal burns in patients 1-month of age and older (removing the prior limitation of use in patients younger than 18 years of age).”
Life of this trial
- Registered 1 year 7 months before it started.
- Ran for about 2 years 3 months before it stopped.
- 19 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- Avita Medical
- Sponsor type
- Industry
- Conditions
- Burns
- Interventions
- RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device; Mepilex® Ag Wound Dressing; Conventional autografting (only when indicated)
- Participants
- 19
- Sites
- 9
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.